2xcq › Citations

Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN
Nature 466 935-40 (2010)
Related entries: 2xco, 2xcr, 2xcs, 2xct

Cited: 315 times
EuropePMC logo PMID: 20686482

Abstract

Despite the success of genomics in identifying new essential bacterial genes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multidrug resistance. Type IIA topoisomerases cleave and religate DNA to regulate DNA topology and are a major class of antibacterial and anticancer drug targets, yet there is no well developed structural basis for understanding drug action. Here we report the 2.1 A crystal structure of a potent, new class, broad-spectrum antibacterial agent in complex with Staphylococcus aureus DNA gyrase and DNA, showing a new mode of inhibition that circumvents fluoroquinolone resistance in this clinically important drug target. The inhibitor 'bridges' the DNA and a transient non-catalytic pocket on the two-fold axis at the GyrA dimer interface, and is close to the active sites and fluoroquinolone binding sites. In the inhibitor complex the active site seems poised to cleave the DNA, with a single metal ion observed between the TOPRIM (topoisomerase/primase) domain and the scissile phosphate. This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.

Reviews - 2xcq mentioned but not cited (2)

  1. Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target. Robinson A, Causer RJ, Dixon NE. Curr Drug Targets 13 352-372 (2012)
  2. DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion. Bax BD, Murshudov G, Maxwell A, Germe T. J Mol Biol 431 3427-3449 (2019)

Articles - 2xcq mentioned but not cited (2)

  1. A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance. Germe T, Vörös J, Jeannot F, Taillier T, Stavenger RA, Bacqué E, Maxwell A, Bax BD. Nucleic Acids Res 46 4114-4128 (2018)
  2. Methanol extract of Black soldier fly (Hermetia illucens) prepupae against Aeromonas and Staphylococcus aureus bacteria in vitro and in silico. Qosimah D, Santoso S, Maftuch M, Khotimah H, Fitri LE, Aulanni'am A, Suwanti LT. Open Vet J 13 48-63 (2023)


Reviews citing this publication (57)

  1. Drugging topoisomerases: lessons and challenges. Pommier Y. ACS Chem Biol 8 82-95 (2013)
  2. Mechanism of quinolone action and resistance. Aldred KJ, Kerns RJ, Osheroff N. Biochemistry 53 1565-1574 (2014)
  3. All tangled up: how cells direct, manage and exploit topoisomerase function. Vos SM, Tretter EM, Schmidt BH, Berger JM. Nat Rev Mol Cell Biol 12 827-841 (2011)
  4. Novel classes of antibiotics or more of the same? Coates AR, Halls G, Hu Y. Br J Pharmacol 163 184-194 (2011)
  5. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Collin F, Karkare S, Maxwell A. Appl Microbiol Biotechnol 92 479-497 (2011)
  6. New mechanistic and functional insights into DNA topoisomerases. Chen SH, Chan NL, Hsieh TS. Annu Rev Biochem 82 139-170 (2013)
  7. Topoisomerases as anticancer targets. Delgado JL, Hsieh CM, Chan NL, Hiasa H. Biochem J 475 373-398 (2018)
  8. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. Hooper DC, Jacoby GA. Cold Spring Harb Perspect Med 6 a025320 (2016)
  9. Interfacial inhibitors: targeting macromolecular complexes. Pommier Y, Marchand C. Nat Rev Drug Discov 11 25-36 (2011)
  10. Challenges of antibacterial discovery revisited. Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ. Ann N Y Acad Sci 1213 5-19 (2010)
  11. Multi-drug-resistant Staphylococcus aureus and future chemotherapy. Hiramatsu K, Katayama Y, Matsuo M, Sasaki T, Morimoto Y, Sekiguchi A, Baba T. J Infect Chemother 20 593-601 (2014)
  12. Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Bush NG, Diez-Santos I, Abbott LR, Maxwell A. Molecules 25 E5662 (2020)
  13. DNA topoisomerase I and DNA gyrase as targets for TB therapy. Nagaraja V, Godbole AA, Henderson SR, Maxwell A. Drug Discov Today 22 510-518 (2017)
  14. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity. Naeem A, Badshah SL, Badshah SL, Muska M, Ahmad N, Khan K. Molecules 21 268 (2016)
  15. Whole-genome sequencing targets drug-resistant bacterial infections. Punina NV, Makridakis NM, Remnev MA, Topunov AF. Hum Genomics 9 19 (2015)
  16. Antibiotics as probes of biological complexity. Falconer SB, Czarny TL, Brown ED. Nat Chem Biol 7 415-423 (2011)
  17. Confronting the challenges of discovery of novel antibacterial agents. Singh SB. Bioorg Med Chem Lett 24 3683-3689 (2014)
  18. Thinking Outside the Box-Novel Antibacterials To Tackle the Resistance Crisis. Lakemeyer M, Zhao W, Mandl FA, Hammann P, Sieber SA. Angew Chem Int Ed Engl 57 14440-14475 (2018)
  19. Time for a change: addressing R&D and commercialization challenges for antibacterials. Payne DJ, Miller LF, Findlay D, Anderson J, Marks L. Philos Trans R Soc Lond B Biol Sci 370 20140086 (2015)
  20. Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Sanyal G, Doig P. Expert Opin Drug Discov 7 327-339 (2012)
  21. DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens. van Eijk E, Wittekoek B, Kuijper EJ, Smits WK. J Antimicrob Chemother 72 1275-1284 (2017)
  22. Biologically active quinoline and quinazoline alkaloids part II. Shang XF, Morris-Natschke SL, Yang GZ, Liu YQ, Guo X, Xu XS, Goto M, Li JC, Zhang JY, Lee KH. Med Res Rev 38 1614-1660 (2018)
  23. Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis. Reiche MA, Warner DF, Mizrahi V. Front Mol Biosci 4 75 (2017)
  24. How to cope with the quest for new antibiotics. Fabbretti A, Gualerzi CO, Brandi L. FEBS Lett 585 1673-1681 (2011)
  25. Interfacial inhibitors. Pommier Y, Kiselev E, Marchand C. Bioorg Med Chem Lett 25 3961-3965 (2015)
  26. Multitarget ligands in antibacterial research: progress and opportunities. East SP, Silver LL. Expert Opin Drug Discov 8 143-156 (2013)
  27. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase. Ehmann DE, Lahiri SD. Curr Opin Pharmacol 18 76-83 (2014)
  28. Antimicrobial resistance (AMR) nanomachines-mechanisms for fluoroquinolone and glycopeptide recognition, efflux and/or deactivation. Phillips-Jones MK, Harding SE. Biophys Rev 10 347-362 (2018)
  29. The mechanism of negative DNA supercoiling: a cascade of DNA-induced conformational changes prepares gyrase for strand passage. Gubaev A, Klostermeier D. DNA Repair (Amst) 16 23-34 (2014)
  30. Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs). Kolarič A, Anderluh M, Minovski N. J Med Chem 63 5664-5674 (2020)
  31. Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials. Walesch S, Birkelbach J, Jézéquel G, Haeckl FPJ, Hegemann JD, Hesterkamp T, Hirsch AKH, Hammann P, Müller R. EMBO Rep 24 e56033 (2023)
  32. Physicochemical Properties of Ion Pairs of Biological Macromolecules. Iwahara J, Esadze A, Zandarashvili L. Biomolecules 5 2435-2463 (2015)
  33. Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections. Scangarella-Oman NE, Hossain M, Hoover JL, Perry CR, Tiffany C, Barth A, Dumont EF. Antimicrob Agents Chemother 66 e0149221 (2022)
  34. New insights into DNA-binding by type IIA topoisomerases. Chang CC, Wang YR, Chen SF, Wu CC, Chan NL. Curr Opin Struct Biol 23 125-133 (2013)
  35. Squaring up to DNA: pentapeptide repeat proteins and DNA mimicry. Shah S, Heddle JG. Appl Microbiol Biotechnol 98 9545-9560 (2014)
  36. Recent progress in the discovery and development of DNA gyrase B inhibitors. Barančoková M, Kikelj D, Ilaš J. Future Med Chem 10 1207-1227 (2018)
  37. The Macromolecular Machines that Duplicate the Escherichia coli Chromosome as Targets for Drug Discovery. Kaguni JM. Antibiotics (Basel) 7 E23 (2018)
  38. Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. Koulenti D, Xu E, Song A, Sum Mok IY, Karageorgopoulos DE, Armaganidis A, Tsiodras S, Lipman J. Microorganisms 8 E191 (2020)
  39. A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone. Bisacchi GS, Hale MR. Curr Med Chem 23 520-577 (2016)
  40. Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review. Azam MA, Thathan J, Jubie S. Bioorg Chem 62 41-63 (2015)
  41. The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae. Rubin DHF, Ross JDC, Grad YH. Transl Res 220 122-137 (2020)
  42. Vibrio cholerae infection, novel drug targets and phage therapy. Fazil MH, Singh DV. Future Microbiol 6 1199-1208 (2011)
  43. The search for novel treatment strategies for Streptococcus pneumoniae infections. Cools F, Delputte P, Cos P. FEMS Microbiol Rev 45 fuaa072 (2021)
  44. Topoisomerases: Resistance versus Sensitivity, How Far We Can Go? Bansal S, Bajaj P, Pandey S, Tandon V. Med Res Rev 37 404-438 (2017)
  45. Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea. Scangarella-Oman NE, Hossain M, Perry CR, Tiffany C, Powell M, Swift B, Dumont EF. Sex Transm Infect 99 64-69 (2023)
  46. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV. Kokot M, Anderluh M, Hrast M, Minovski N. J Med Chem 65 6431-6440 (2022)
  47. Structural insights into simocyclinone as an antibiotic, effector ligand and substrate. Buttner MJ, Schäfer M, Lawson DM, Maxwell A. FEMS Microbiol Rev 42 (2018)
  48. Towards Conformation-Sensitive Inhibition of Gyrase: Implications of Mechanistic Insight for the Identification and Improvement of Inhibitors. Klostermeier D. Molecules 26 1234 (2021)
  49. Understanding the structural mechanisms of antibiotic resistance sets the platform for new discovery. Reeve SM, Lombardo MN, Anderson AC. Future Microbiol 10 1727-1733 (2015)
  50. Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV. Grossman S, Fishwick CWG, McPhillie MJ. Pharmaceuticals (Basel) 16 261 (2023)
  51. What's on the Other Side of the Gate: A Structural Perspective on DNA Gate Opening of Type IA and IIA DNA Topoisomerases. Vidmar V, Vayssières M, Lamour V. Int J Mol Sci 24 3986 (2023)
  52. Why Matter Matters: Fast-Tracking Mycobacterium abscessus Drug Discovery. Ganapathy US, Dick T. Molecules 27 6948 (2022)
  53. Antibiotic Susceptibility Testing with Raman Biosensing. Novikov A, Sayfutdinova A, Botchkova E, Kopitsyn D, Fakhrullin R. Antibiotics (Basel) 11 1812 (2022)
  54. Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases? Bax BD, Sutormin D, McDonald NQ, Burley GA, Shelkovnikova T. Int J Mol Sci 23 11541 (2022)
  55. Review on the Developments of Benzothiazole-containing Antimicrobial Agents. Haroun M. Curr Top Med Chem 22 2630-2659 (2022)
  56. Yeast: a microbe with macro-implications to antimicrobial drug discovery. Balibar CJ, Roemer T. Brief Funct Genomics 15 147-154 (2016)
  57. [New antibiotics for the treatment of urinary tract infections]. Wagenlehner FME. Urologie 62 705-710 (2023)

Articles citing this publication (254)

  1. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL. Science 333 459-462 (2011)
  2. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD. Nat Struct Mol Biol 17 1152-1153 (2010)
  3. Discovery research: the scientific challenge of finding new antibiotics. Livermore DM, British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. J Antimicrob Chemother 66 1941-1944 (2011)
  4. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM. J Mol Biol 424 109-124 (2012)
  5. Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity. Schmidt BH, Osheroff N, Berger JM. Nat Struct Mol Biol 19 1147-1154 (2012)
  6. Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Blower TR, Williamson BH, Kerns RJ, Berger JM. Proc Natl Acad Sci U S A 113 1706-1713 (2016)
  7. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Aldred KJ, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Nucleic Acids Res 41 4628-4639 (2013)
  8. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. Antimicrob Agents Chemother 60 1918-1923 (2016)
  9. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. Mustaev A, Malik M, Zhao X, Kurepina N, Luan G, Oppegard LM, Hiasa H, Marks KR, Kerns RJ, Berger JM, Drlica K. J Biol Chem 289 12300-12312 (2014)
  10. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase. Gibson EG, Bax B, Chan PF, Osheroff N. ACS Infect Dis 5 570-581 (2019)
  11. Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation. Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, Perry CR, Raychaudhuri A, Scangarella-Oman NE, Hossain M, Dumont EF. Clin Infect Dis 67 504-512 (2018)
  12. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Rimbara E, Noguchi N, Kawai T, Sasatsu M. Helicobacter 17 36-42 (2012)
  13. DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA. Lee S, Jung SR, Heo K, Byl JA, Deweese JE, Osheroff N, Hohng S. Proc Natl Acad Sci U S A 109 2925-2930 (2012)
  14. Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin. Chan PF, Srikannathasan V, Huang J, Cui H, Fosberry AP, Gu M, Hann MM, Hibbs M, Homes P, Ingraham K, Pizzollo J, Shen C, Shillings AJ, Spitzfaden CE, Tanner R, Theobald AJ, Stavenger RA, Bax BD, Gwynn MN. Nat Commun 6 10048 (2015)
  15. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Aldred KJ, McPherson SA, Wang P, Kerns RJ, Graves DE, Turnbough CL, Osheroff N. Biochemistry 51 370-381 (2012)
  16. Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections. O'Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, Dumont E. Antimicrob Agents Chemother 61 e02095-16 (2017)
  17. Cryo-EM structure of the complete E. coli DNA gyrase nucleoprotein complex. Vanden Broeck A, Lotz C, Ortiz J, Lamour V. Nat Commun 10 4935 (2019)
  18. Copper(II)-catalyzed three-component cascade annulation of diaryliodoniums, nitriles, and alkynes: a regioselective synthesis of multiply substituted quinolines. Wang Y, Chen C, Peng J, Li M. Angew Chem Int Ed Engl 52 5323-5327 (2013)
  19. Structural insight into negative DNA supercoiling by DNA gyrase, a bacterial type 2A DNA topoisomerase. Papillon J, Ménétret JF, Batisse C, Hélye R, Schultz P, Potier N, Lamour V. Nucleic Acids Res 41 7815-7827 (2013)
  20. ATP binding controls distinct structural transitions of Escherichia coli DNA gyrase in complex with DNA. Basu A, Schoeffler AJ, Berger JM, Bryant Z. Nat Struct Mol Biol 19 538-46, S1 (2012)
  21. Evolution toward high-level fluoroquinolone resistance in Francisella species. Sutera V, Levert M, Burmeister WP, Schneider D, Maurin M. J Antimicrob Chemother 69 101-110 (2014)
  22. Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae. Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany CA, Perry CR, Raychaudhuri A, Dumont EF, Huang J, Hook EW, Miller LA. Antimicrob Agents Chemother 62 e01221-18 (2018)
  23. Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases. Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS, Brown P, Cailleau N, Chen D, Dabbs S, Davies DT, Esken JM, Giordano I, Hoover JL, Huang J, Jones GE, Sukmar SK, Spitzfaden C, Markwell RE, Minthorn EA, Rittenhouse S, Gwynn MN, Pearson ND. Bioorg Med Chem Lett 23 5437-5441 (2013)
  24. The role of DNA bending in type IIA topoisomerase function. Lee I, Dong KC, Berger JM. Nucleic Acids Res 41 5444-5456 (2013)
  25. Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents. Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen D, Lagrutta A, Bradley P, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Wei C, Fukuda H, Kishii R, Takei M, Fukuda Y. ACS Med Chem Lett 5 609-614 (2014)
  26. Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria. Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE, Sader HS. Antimicrob Agents Chemother 61 e00468-17 (2017)
  27. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Sanfilippo CM, Hesje CK, Haas W, Morris TW. Chemotherapy 57 363-371 (2011)
  28. Molecular basis of antibiotic multiresistance transfer in Staphylococcus aureus. Edwards JS, Betts L, Frazier ML, Pollet RM, Kwong SM, Walton WG, Ballentine WK, Huang JJ, Habibi S, Del Campo M, Meier JL, Dervan PB, Firth N, Redinbo MR. Proc Natl Acad Sci U S A 110 2804-2809 (2013)
  29. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. Mitton-Fry MJ, Brickner SJ, Hamel JC, Brennan L, Casavant JM, Chen M, Chen T, Ding X, Driscoll J, Hardink J, Hoang T, Hua E, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Plotkin M, Reilly U, Robinson S, Schafer J, Shepard RM, Smith JF, Stone GG, Subramanyam C, Yoon K, Yuan W, Zaniewski RP, Zook C. Bioorg Med Chem Lett 23 2955-2961 (2013)
  30. Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport. Laponogov I, Veselkov DA, Crevel IM, Pan XS, Fisher LM, Sanderson MR. Nucleic Acids Res 41 9911-9923 (2013)
  31. Design, synthesis, and evaluation of novel fluoroquinolone-flavonoid hybrids as potent antibiotics against drug-resistant microorganisms. Xiao ZP, Wang XD, Wang PF, Zhou Y, Zhang JW, Zhang L, Zhou J, Zhou SS, Ouyang H, Lin XY, Mustapa M, Reyinbaike A, Zhu HL. Eur J Med Chem 80 92-100 (2014)
  32. In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. Antimicrob Agents Chemother 61 e02047-16 (2017)
  33. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M. J Antimicrob Chemother 73 2072-2077 (2018)
  34. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Malik M, Marks KR, Mustaev A, Zhao X, Chavda K, Kerns RJ, Drlica K. Antimicrob Agents Chemother 55 2335-2343 (2011)
  35. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE. Antimicrob Agents Chemother 58 2657-2664 (2014)
  36. Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate. Chen SF, Huang NL, Lin JH, Wu CC, Wang YR, Yu YJ, Gilson MK, Chan NL. Nat Commun 9 3085 (2018)
  37. Microspectrometric insights on the uptake of antibiotics at the single bacterial cell level. Cinquin B, Maigre L, Pinet E, Chevalier J, Stavenger RA, Mills S, Réfrégiers M, Pagès JM. Sci Rep 5 17968 (2015)
  38. Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. Aldred KJ, Breland EJ, Vlčková V, Strub MP, Neuman KC, Kerns RJ, Osheroff N. Biochemistry 53 5558-5567 (2014)
  39. Graphene film doped with silver nanoparticles: self-assembly formation, structural characterizations, antibacterial ability, and biocompatibility. Zhang P, Wang H, Zhang X, Xu W, Li Y, Li Q, Wei G, Wei G, Su Z. Biomater Sci 3 852-860 (2015)
  40. Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design. Drlica K, Mustaev A, Towle TR, Luan G, Kerns RJ, Berger JM. ACS Chem Biol 9 2895-2904 (2014)
  41. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Kim H, Nakajima C, Yokoyama K, Rahim Z, Kim YU, Oguri H, Suzuki Y. Antimicrob Agents Chemother 55 3661-3667 (2011)
  42. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors. Jeankumar VU, Renuka J, Santosh P, Soni V, Sridevi JP, Suryadevara P, Yogeeswari P, Sriram D. Eur J Med Chem 70 143-153 (2013)
  43. Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria. Parkinson EI, Bair JS, Nakamura BA, Lee HY, Kuttab HI, Southgate EH, Lezmi S, Lau GW, Hergenrother PJ. Nat Commun 6 6947 (2015)
  44. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs. Blanco D, Perez-Herran E, Cacho M, Ballell L, Castro J, González Del Río R, Lavandera JL, Remuiñán MJ, Richards C, Rullas J, Vázquez-Muñiz MJ, Woldu E, Zapatero-González MC, Angulo-Barturen I, Mendoza A, Barros D. Antimicrob Agents Chemother 59 1868-1875 (2015)
  45. The metabolism and disposition of GSK2140944 in healthy human subjects. Negash K, Andonian C, Felgate C, Chen C, Goljer I, Squillaci B, Nguyen D, Pirhalla J, Lev M, Schubert E, Tiffany C, Hossain M, Ho M. Xenobiotica 46 683-702 (2016)
  46. Mode of action of closthioamide: the first member of the polythioamide class of bacterial DNA gyrase inhibitors. Chiriac AI, Kloss F, Krämer J, Vuong C, Hertweck C, Sahl HG. J Antimicrob Chemother 70 2576-2588 (2015)
  47. Mycobacterium fluoroquinolone resistance protein B, a novel small GTPase, is involved in the regulation of DNA gyrase and drug resistance. Tao J, Han J, Wu H, Hu X, Deng J, Fleming J, Maxwell A, Bi L, Mi K. Nucleic Acids Res 41 2370-2381 (2013)
  48. A new crystal structure of the bifunctional antibiotic simocyclinone D8 bound to DNA gyrase gives fresh insight into the mechanism of inhibition. Hearnshaw SJ, Edwards MJ, Stevenson CE, Lawson DM, Maxwell A. J Mol Biol 426 2023-2033 (2014)
  49. Characterization of flavonol inhibition of DnaB helicase: real-time monitoring, structural modeling, and proposed mechanism. Lin HH, Huang CY. J Biomed Biotechnol 2012 735368 (2012)
  50. Local sensing of global DNA topology: from crossover geometry to type II topoisomerase processivity. Timsit Y. Nucleic Acids Res 39 8665-8676 (2011)
  51. Palladium-catalyzed sequential formation of C-C bonds: efficient assembly of 2-substituted and 2,3-disubstituted quinolines. Ji X, Huang H, Li Y, Chen H, Jiang H. Angew Chem Int Ed Engl 51 7292-7296 (2012)
  52. Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis). Overcash JS, Tiffany CA, Scangarella-Oman NE, Perry CR, Tao Y, Hossain M, Barth A, Dumont EF. Antimicrob Agents Chemother 64 e00199-20 (2020)
  53. Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase. Chan PF, Germe T, Bax BD, Huang J, Thalji RK, Bacqué E, Checchia A, Chen D, Cui H, Ding X, Ingraham K, McCloskey L, Raha K, Srikannathasan V, Maxwell A, Stavenger RA. Proc Natl Acad Sci U S A 114 E4492-E4500 (2017)
  54. Topoisomerase II minimizes DNA entanglements by proofreading DNA topology after DNA strand passage. Martínez-García B, Fernández X, Díaz-Ingelmo O, Rodríguez-Campos A, Manichanh C, Roca J. Nucleic Acids Res 42 1821-1830 (2014)
  55. Antibacterial Evaluation, In Silico Characters and Molecular Docking of Schiff Bases Derived from 5-aminopyrazoles. Hassan AS, Askar AA, Nossier ES, Naglah AM, Moustafa GO, Al-Omar MA. Molecules 24 E3130 (2019)
  56. Characterization of Staphylococcus aureus Primosomal DnaD Protein: Highly Conserved C-Terminal Region Is Crucial for ssDNA and PriA Helicase Binding but Not for DnaA Protein-Binding and Self-Tetramerization. Huang YH, Lien Y, Huang CC, Huang CY. PLoS One 11 e0157593 (2016)
  57. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. Renuka J, Reddy KI, Srihari K, Jeankumar VU, Shravan M, Sridevi JP, Yogeeswari P, Babu KS, Sriram D. Bioorg Med Chem 22 4924-4934 (2014)
  58. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria. Charrier C, Salisbury AM, Savage VJ, Duffy T, Moyo E, Chaffer-Malam N, Ooi N, Newman R, Cheung J, Metzger R, McGarry D, Pichowicz M, Sigerson R, Cooper IR, Nelson G, Butler HS, Craighead M, Ratcliffe AJ, Best SA, Stokes NR. Antimicrob Agents Chemother 61 e02100-16 (2017)
  59. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors. Medapi B, Renuka J, Saxena S, Sridevi JP, Medishetti R, Kulkarni P, Yogeeswari P, Sriram D. Bioorg Med Chem 23 2062-2078 (2015)
  60. Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads. Jeankumar VU, Renuka J, Pulla VK, Soni V, Sridevi JP, Suryadevara P, Shravan M, Medishetti R, Kulkarni P, Yogeeswari P, Sriram D. Int J Antimicrob Agents 43 269-278 (2014)
  61. Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus. Lahiri SD, Kutschke A, McCormack K, Alm RA. Antimicrob Agents Chemother 59 5278-5287 (2015)
  62. Mapping the spectrum of conformational states of the DNA- and C-gates in Bacillus subtilis gyrase. Rudolph MG, Klostermeier D. J Mol Biol 425 2632-2640 (2013)
  63. Structure based in silico analysis of quinolone resistance in clinical isolates of Salmonella Typhi from India. Kumar M, Dahiya S, Sharma P, Sharma S, Singh TP, Kapil A, Kaur P. PLoS One 10 e0126560 (2015)
  64. Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration. Luan G, Hong Y, Drlica K, Zhao X. Antimicrob Agents Chemother 62 e01622-17 (2018)
  65. News The antibacterial lead discovery challenge. Nat Rev Drug Discov 9 751-752 (2010)
  66. Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study. Abdel-Aziz AA, Asiri YA, Al-Agamy MH. Eur J Med Chem 46 5487-5497 (2011)
  67. Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors. Geng B, Comita-Prevoir J, Eyermann CJ, Reck F, Fisher S. Bioorg Med Chem Lett 21 5432-5435 (2011)
  68. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons. Gibson EG, Blower TR, Cacho M, Bax B, Berger JM, Osheroff N. ACS Infect Dis 4 1211-1222 (2018)
  69. The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA. Gilroy KL, Austin CA. PLoS One 6 e14693 (2011)
  70. Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV. Pitts SL, Liou GF, Mitchenall LA, Burgin AB, Maxwell A, Neuman KC, Osheroff N. Nucleic Acids Res 39 4808-4817 (2011)
  71. Application of a novel microtitre plate-based assay for the discovery of new inhibitors of DNA gyrase and DNA topoisomerase VI. Taylor JA, Mitchenall LA, Rejzek M, Field RA, Maxwell A. PLoS One 8 e58010 (2013)
  72. Characterisation of novel mutations involved in quinolone resistance in Escherichia coli isolated from imported shrimp. Nawaz M, Sung K, Kweon O, Khan S, Nawaz S, Steele R. Int J Antimicrob Agents 45 471-476 (2015)
  73. Controlling the kinetic and thermodynamic stability of cationic clusters by the addition of molecules or counterions. Strate A, Niemann T, Ludwig R. Phys Chem Chem Phys 19 18854-18862 (2017)
  74. Distinct regions of the Escherichia coli ParC C-terminal domain are required for substrate discrimination by topoisomerase IV. Vos SM, Lee I, Berger JM. J Mol Biol 425 3029-3045 (2013)
  75. Elucidation of DnaE as the Antibacterial Target of the Natural Product, Nargenicin. Painter RE, Adam GC, Arocho M, DiNunzio E, Donald RG, Dorso K, Genilloud O, Gill C, Goetz M, Hairston NN, Murgolo N, Nare B, Olsen DB, Powles M, Racine F, Su J, Vicente F, Wisniewski D, Xiao L, Hammond M, Young K. Chem Biol 22 1362-1373 (2015)
  76. Structural Dynamics and Mechanochemical Coupling in DNA Gyrase. Basu A, Parente AC, Bryant Z. J Mol Biol 428 1833-1845 (2016)
  77. Synthesis, anti-microbial activity, cytotoxicity of some novel substituted (5-(3-(1H-benzo[d]imidazol-2-yl)-4-hydroxybenzyl)benzofuran-2-yl)(phenyl)methanone analogs. Shankar B, Jalapathi P, Saikrishna B, Perugu S, Manga V. Chem Cent J 12 1 (2018)
  78. Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV. Savage VJ, Charrier C, Salisbury AM, Moyo E, Forward H, Chaffer-Malam N, Metzger R, Huxley A, Kirk R, Uosis-Martin M, Noonan G, Mohmed S, Best SA, Ratcliffe AJ, Stokes NR. J Antimicrob Chemother 71 1905-1913 (2016)
  79. Investigating mycobacterial topoisomerase I mechanism from the analysis of metal and DNA substrate interactions at the active site. Cao N, Tan K, Annamalai T, Joachimiak A, Tse-Dinh YC. Nucleic Acids Res 46 7296-7308 (2018)
  80. Making space for anti-infective drug discovery. Nathan C. Cell Host Microbe 9 343-348 (2011)
  81. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. So W, Crandon JL, Nicolau DP. Antimicrob Agents Chemother 59 4956-4961 (2015)
  82. Preparation, antibacterial evaluation and preliminary structure-activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives. Ouyang L, Huang Y, Zhao Y, He G, Xie Y, Liu J, He J, Liu B, Wei Y. Bioorg Med Chem Lett 22 3044-3049 (2012)
  83. Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus. Perlmutter JI, Forbes LT, Krysan DJ, Ebsworth-Mojica K, Colquhoun JM, Wang JL, Dunman PM, Flaherty DP. J Med Chem 57 8540-8562 (2014)
  84. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2). Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Sherer E, Joyce LA, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takano H, Shibasaki M, Yajima M, Nishimura A, Shibata T, Fukuda Y. Bioorg Med Chem Lett 25 1831-1835 (2015)
  85. Research Support, Non-U.S. Gov't Advances in structure-based drug design of novel bacterial topoisomerase inhibitors. Widdowson K, Hennessy A. Future Med Chem 2 1619-1622 (2010)
  86. CryoEM structures of open dimers of gyrase A in complex with DNA illuminate mechanism of strand passage. Soczek KM, Grant T, Rosenthal PB, Mondragón A. Elife 7 e41215 (2018)
  87. DNA gyrase with a single catalytic tyrosine can catalyze DNA supercoiling by a nicking-closing mechanism. Gubaev A, Weidlich D, Klostermeier D. Nucleic Acids Res 44 10354-10366 (2016)
  88. Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. Ross JE, Scangarella-Oman NE, Flamm RK, Jones RN. J Clin Microbiol 52 2629-2632 (2014)
  89. Evaluating the genotoxicity of topoisomerase-targeted antibiotics. Smart DJ, Lynch AM. Mutagenesis 27 359-365 (2012)
  90. N-Benzyl-3-sulfonamidopyrrolidines are a New Class of Bacterial DNA Gyrase Inhibitors. Foss MH, Hurley KA, Sorto N, Lackner LL, Thornton KM, Shaw JT, Weibel DB. ACS Med Chem Lett 2 289-292 (2011)
  91. Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor. Nayar AS, Dougherty TJ, Reck F, Thresher J, Gao N, Shapiro AB, Ehmann DE. Antimicrob Agents Chemother 59 331-337 (2015)
  92. The challenge of developing robust drugs to overcome resistance. Anderson AC, Pollastri MP, Schiffer CA, Peet NP. Drug Discov Today 16 755-761 (2011)
  93. Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing. Hameed P S, Raichurkar A, Madhavapeddi P, Menasinakai S, Sharma S, Kaur P, Nandishaiah R, Panduga V, Reddy J, Sambandamurthy VK, Sriram D. ACS Med Chem Lett 5 820-825 (2014)
  94. Exploring the mode of action of bioactive compounds by microfluidic transcriptional profiling in mycobacteria. Murima P, de Sessions PF, Lim V, Naim AN, Bifani P, Boshoff HI, Sambandamurthy VK, Dick T, Hibberd ML, Schreiber M, Rao SP. PLoS One 8 e69191 (2013)
  95. Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases. Arnoldi E, Pan XS, Fisher LM. Nucleic Acids Res 41 9411-9423 (2013)
  96. Gyramides prevent bacterial growth by inhibiting DNA gyrase and altering chromosome topology. Rajendram M, Hurley KA, Foss MH, Thornton KM, Moore JT, Shaw JT, Weibel DB. ACS Chem Biol 9 1312-1319 (2014)
  97. Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase. Kumar R, Madhumathi BS, Nagaraja V. Antimicrob Agents Chemother 58 2013-2020 (2014)
  98. Pharmacokinetics of Gepotidacin in Renal Impairment. Hossain M, Tiffany C, Raychaudhuri A, Nguyen D, Tai G, Alcorn H, Preston RA, Marbury T, Dumont E. Clin Pharmacol Drug Dev 9 560-572 (2020)
  99. Secalonic acid D as a novel DNA topoisomerase I inhibitor from marine lichen-derived fungus Gliocladium sp. T31. Hong R. Pharm Biol 49 796-799 (2011)
  100. TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p. Wang T, Lu J, Wang R, Cao W, Xu J. J Cancer 13 589-601 (2022)
  101. A diversity-oriented rhodamine library for wide-spectrum bactericidal agents with low inducible resistance against resistant pathogens. Luo X, Qian L, Xiao Y, Tang Y, Zhao Y, Wang X, Gu L, Lei Z, Bao J, Wu J, He T, Hu F, Zheng J, Li H, Zhu W, Shao L, Dong X, Chen D, Qian X, Yang Y. Nat Commun 10 258 (2019)
  102. Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach. Sood D, Kumar N, Singh A, Sakharkar MK, Tomar V, Chandra R. Genomics Inform 16 44-51 (2018)
  103. Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors. Paneth A, Stączek P, Plech T, Strzelczyk A, Dzitko K, Wujec M, Kuśmierz E, Kosikowska U, Grzegorczyk A, Paneth P. J Enzyme Inhib Med Chem 31 14-22 (2016)
  104. Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3). Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Gill C, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takeuchi T, Shibue T, Ohata K, Takano H, Ban S, Nishimura A, Fukuda Y. Bioorg Med Chem Lett 25 2473-2478 (2015)
  105. Induction of mycobacterial resistance to quinolone class antimicrobials. Malik M, Chavda K, Zhao X, Shah N, Hussain S, Kurepina N, Kreiswirth BN, Kerns RJ, Drlica K. Antimicrob Agents Chemother 56 3879-3887 (2012)
  106. Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants. Barth A, Hossain M, Brimhall DB, Perry CR, Tiffany CA, Xu S, Dumont EF. Antimicrob Agents Chemother 66 e0126321 (2022)
  107. Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells. Shi ZY, Li YQ, Kang YH, Hu GQ, Huang-fu CS, Deng JB, Liu B. Acta Pharmacol Sin 33 271-278 (2012)
  108. Probing linker design in citric acid-ciprofloxacin conjugates. Milner SJ, Snelling AM, Kerr KG, Abd-El-Aziz A, Thomas GH, Hubbard RE, Routledge A, Duhme-Klair AK. Bioorg Med Chem 22 4499-4505 (2014)
  109. Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase. Laponogov I, Pan XS, Veselkov DA, Skamrova GB, Umrekar TR, Fisher LM, Sanderson MR. Nat Commun 9 2579 (2018)
  110. Direct control of type IIA topoisomerase activity by a chromosomally encoded regulatory protein. Vos SM, Lyubimov AY, Hershey DM, Schoeffler AJ, Sengupta S, Nagaraja V, Berger JM. Genes Dev 28 1485-1497 (2014)
  111. Dynamic coupling between conformations and nucleotide states in DNA gyrase. Basu A, Hobson M, Lebel P, Fernandes LE, Tretter EM, Berger JM, Bryant Z. Nat Chem Biol 14 565-574 (2018)
  112. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling. Jeankumar VU, Reshma RS, Janupally R, Saxena S, Sridevi JP, Medapi B, Kulkarni P, Yogeeswari P, Sriram D. Org Biomol Chem 13 2423-2431 (2015)
  113. Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance. Ashley RE, Lindsey RH, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Biochemistry 56 4191-4200 (2017)
  114. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. Mitton-Fry MJ, Brickner SJ, Hamel JC, Barham R, Brennan L, Casavant JM, Ding X, Finegan S, Hardink J, Hoang T, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Subramanyam C, Plotkin M, Reilly U, Schafer J, Stone GG, Uccello DP, Wisialowski T, Yoon K, Zaniewski R, Zook C. Bioorg Med Chem Lett 27 3353-3358 (2017)
  115. Research Support, Non-U.S. Gov't Novel bacterial topoisomerase inhibitors: challenges and perspectives in reducing hERG toxicity. Kolarič A, Minovski N. Future Med Chem 10 2241-2244 (2018)
  116. Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds. Kolarič A, Germe T, Hrast M, Stevenson CEM, Lawson DM, Burton NP, Vörös J, Maxwell A, Minovski N, Anderluh M. Nat Commun 12 150 (2021)
  117. Topoisomerase II from Human Malaria Parasites: EXPRESSION, PURIFICATION, AND SELECTIVE INHIBITION. Mudeppa DG, Kumar S, Kokkonda S, White J, Rathod PK. J Biol Chem 290 20313-20324 (2015)
  118. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV. Gibson EG, Oviatt AA, Cacho M, Neuman KC, Chan PF, Osheroff N. Biochemistry 58 4447-4455 (2019)
  119. Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis. Minovski N, Perdih A, Novic M, Solmajer T. J Comput Chem 34 790-801 (2013)
  120. Discovery of a Novel DNA Gyrase-Targeting Antibiotic through the Chemical Perturbation of Streptomyces venezuelae Sporulation. McAuley S, Huynh A, Howells A, Walpole C, Maxwell A, Nodwell JR. Cell Chem Biol 26 1274-1282.e4 (2019)
  121. Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones. Laponogov I, Pan XS, Veselkov DA, Cirz RT, Wagman A, Moser HE, Fisher LM, Sanderson MR. Open Biol 6 160157 (2016)
  122. In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Waites KB, Crabb DM, Xiao L, Duffy LB. Antimicrob Agents Chemother 61 e01064-17 (2017)
  123. In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase. Tan CM, Gill CJ, Wu J, Toussaint N, Yin J, Tsuchiya T, Garlisi CG, Kaelin D, Meinke PT, Miesel L, Olsen DB, Lagrutta A, Fukuda H, Kishii R, Takei M, Oohata K, Takeuchi T, Shibue T, Takano H, Nishimura A, Fukuda Y, Singh SB. Antimicrob Agents Chemother 60 4830-4839 (2016)
  124. Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. Reck F, Ehmann DE, Dougherty TJ, Newman JV, Hopkins S, Stone G, Agrawal N, Ciaccio P, McNulty J, Barthlow H, O'Donnell J, Goteti K, Breen J, Comita-Prevoir J, Cornebise M, Cronin M, Eyermann CJ, Geng B, Carr GR, Pandarinathan L, Tang X, Cottone A, Zhao L, Bezdenejnih-Snyder N. Bioorg Med Chem 22 5392-5409 (2014)
  125. Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection Model. VanScoy BD, Scangarella-Oman NE, Fikes S, Min S, Huang J, Ingraham K, Bhavnani SM, Conde H, Ambrose PG. Antimicrob Agents Chemother 64 e00521-20 (2020)
  126. Selection of DNA Cleavage Sites by Topoisomerase II Results from Enzyme-Induced Flexibility of DNA. Jang Y, Son H, Lee SW, Hwang W, Jung SR, Byl JAW, Osheroff N, Lee S. Cell Chem Biol 26 502-511.e3 (2019)
  127. Structure activity relationship of substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-4). Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Shibata T, Ohata K, Takano H, Kurasaki H, Takeuchi T, Nishimura A, Fukuda Y. Bioorg Med Chem Lett 25 2409-2415 (2015)
  128. Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. Malik M, Mustaev A, Schwanz HA, Luan G, Shah N, Oppegard LM, de Souza EC, Hiasa H, Zhao X, Kerns RJ, Drlica K. Nucleic Acids Res 44 3304-3316 (2016)
  129. In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium. Jensen JS, Nørgaard C, Scangarella-Oman N, Unemo M. Emerg Microbes Infect 9 1388-1392 (2020)
  130. A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents. Blower TR, Bandak A, Lee ASY, Austin CA, Nitiss JL, Berger JM. Nucleic Acids Res 47 8163-8179 (2019)
  131. Antibacterial activity of enrofloxacin and ciprofloxacin derivatives of β-octaarginine. Purkayastha N, Capone S, Beck AK, Seebach D, Leeds J, Thompson K, Moser HE. Chem Biodivers 12 179-193 (2015)
  132. Ciprofloxacin containing Mannich base and its copper complex induce antitumor activity via different mechanism of action. Fu Y, Yang Y, Zhou S, Liu Y, Yuan Y, Li S, Li C. Int J Oncol 45 2092-2100 (2014)
  133. Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones. Haas W, Sanfilippo CM, Hesje CK, Morris TW. Clin Ophthalmol 7 821-830 (2013)
  134. Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase. Towle TR, Kulkarni CA, Oppegard LM, Williams BP, Picha TA, Hiasa H, Kerns RJ. Bioorg Med Chem Lett 28 1903-1910 (2018)
  135. Evybactin is a DNA gyrase inhibitor that selectively kills Mycobacterium tuberculosis. Imai Y, Hauk G, Quigley J, Liang L, Son S, Ghiglieri M, Gates MF, Morrissette M, Shahsavari N, Niles S, Baldisseri D, Honrao C, Ma X, Guo JJ, Berger JM, Lewis K. Nat Chem Biol 18 1236-1244 (2022)
  136. Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems. VanScoy BD, Lakota EA, Conde H, Fikes S, Bhavnani SM, Elefante PB, Scangarella-Oman NE, Ambrose PG. Antimicrob Agents Chemother 65 e0012221 (2021)
  137. In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections. Scangarella-Oman NE, Ingraham KA, Tiffany CA, Tomsho L, Van Horn SF, Mayhew DN, Perry CR, Ashton TC, Dumont EF, Huang J, Brown JR, Miller LA. Antimicrob Agents Chemother 64 e01302-19 (2020)
  138. Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226. Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE, Flamm RK. Antimicrob Agents Chemother 60 4404-4406 (2016)
  139. Triazolo Based-Thiadiazole Derivatives. Synthesis, Biological Evaluation and Molecular Docking Studies. Kamoutsis C, Fesatidou M, Petrou A, Geronikaki A, Poroikov V, Ivanov M, Soković M, Ćirić A, Carazo A, Mladěnka P. Antibiotics (Basel) 10 804 (2021)
  140. A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus. Ganapathy US, Del Río RG, Cacho-Izquierdo M, Ortega F, Lelièvre J, Barros-Aguirre D, Aragaw WW, Zimmerman MD, Lindman M, Dartois V, Gengenbacher M, Dick T. Antimicrob Agents Chemother 65 e0151421 (2021)
  141. Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells. Peyrusson F, Tulkens PM, Van Bambeke F. Antimicrob Agents Chemother 62 e02245-17 (2018)
  142. Chromanyl-isoxazolidines as Antibacterial agents: Synthesis, Biological Evaluation, Quantitative Structure Activity Relationship, and Molecular Docking Studies. Singh G, Sharma A, Kaur H, Ishar MP. Chem Biol Drug Des 87 213-223 (2016)
  143. Efficacy of Human Exposures of Gepotidacin (GSK2140944) against Escherichia coli in a Rat Pyelonephritis Model. Hoover JL, Singley CM, Elefante P, Rittenhouse S. Antimicrob Agents Chemother 63 e00086-19 (2019)
  144. Functional Analyses of the Toxoplasma gondii DNA Gyrase Holoenzyme: A Janus Topoisomerase with Supercoiling and Decatenation Abilities. Lin TY, Nagano S, Gardiner Heddle J. Sci Rep 5 14491 (2015)
  145. New rhenium complexes with ciprofloxacin as useful models for understanding the properties of [99mTc]-ciprofloxacin radiopharmaceutical. Lecina J, Cortés P, Llagostera M, Piera C, Suades J. Bioorg Med Chem 22 3262-3269 (2014)
  146. Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment. Hossain M, Tiffany C, Tao Y, Barth A, Marbury TC, Preston RA, Dumont E. Clin Pharmacol Drug Dev 10 588-597 (2021)
  147. Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6). Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei C, Liao Y, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Yajima M, Shibue T, Shibata T, Ohata K, Nishimura A, Fukuda Y. Bioorg Med Chem Lett 25 3636-3643 (2015)
  148. Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space. Ross AG, Benton BM, Chin D, De Pascale G, Fuller J, Leeds JA, Reck F, Richie DL, Vo J, LaMarche MJ. Bioorg Med Chem Lett 25 3468-3475 (2015)
  149. Trimethoxy-benzaldehyde levofloxacin hydrazone inducing the growth arrest and apoptosis of human hepatocarcinoma cells. Sun JP, Shi ZY, Liu SM, Kang YH, Hu GQ, Huangfu CS, Deng JB, Liu B. Cancer Cell Int 13 67 (2013)
  150. α,β-Functionalization of saturated ketones with anthranils via Cu-catalyzed sequential dehydrogenation/aza-Michael addition/annulation cascade reactions in one-pot. Tiwari DK, Phanindrudu M, Wakade SB, Nanubolu JB, Tiwari DK. Chem Commun (Camb) 53 5302-5305 (2017)
  151. Chemical Composition and the Anticancer, Antimicrobial, and Antioxidant Properties of Acacia Honey from the Hail Region: The in vitro and in silico Investigation. Hamadou WS, Bouali N, Badraoui R, Hadj Lajimi R, Hamdi A, Alreshidi M, Patel M, Adnan M, Siddiqui AJ, Noumi E, Rao Pasupuleti V, Snoussi M. Evid Based Complement Alternat Med 2022 1518511 (2022)
  152. Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus. Lu Y, Papa JL, Nolan S, English A, Seffernick JT, Shkolnikov N, Powell J, Lindert S, Wozniak DJ, Yalowich J, Mitton-Fry MJ. ACS Med Chem Lett 11 2446-2454 (2020)
  153. Dynamic interaction of fluoroquinolones with magnesium ions monitored using bacterial outer membrane nanopores. Wang J, Prajapati JD, Kleinekathöfer U, Winterhalter M. Chem Sci 11 10344-10353 (2020)
  154. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus. Lepak AJ, Seiler P, Surivet JP, Ritz D, Kohl C, Andes DR. Antimicrob Agents Chemother 60 3626-3632 (2016)
  155. Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding. Hameed P S, Manjrekar P, Raichurkar A, Shinde V, Puttur J, Shanbhag G, Chinnapattu M, Patil V, Rudrapatana S, Sharma S, Kumar CN, Nandishaiah R, Madhavapeddi P, Sriram D, Solapure S, Sambandamurthy VK. ACS Med Chem Lett 6 741-746 (2015)
  156. New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors. Gençer HK, Levent S, Acar Çevik U, Özkay Y, Ilgın S. Bioorg Med Chem Lett 27 1162-1168 (2017)
  157. New Topoisomerase Inhibitors: Evaluating the Potency of Gepotidacin and Zoliflodacin in Fluoroquinolone-Resistant Escherichia coli upon tolC Inactivation and Differentiating Their Efflux Pump Substrate Nature. Schuster S, Vavra M, Köser R, Rossen JWA, Kern WV. Antimicrob Agents Chemother 65 e01803-20 (2021)
  158. Novel N-(Substituted) Thioacetamide Quinazolinone Benzenesulfonamides as Antimicrobial Agents. Ghorab MM, Alqahtani AS, Soliman AM, Askar AA. Int J Nanomedicine 15 3161-3180 (2020)
  159. Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site. Franco-Ulloa S, La Sala G, Miscione GP, De Vivo M. Int J Mol Sci 19 E453 (2018)
  160. Palladium-catalyzed synthesis of polysubstituted quinolines from 2-amino aromatic ketones and alkynes. Zhou W, Lei J. Chem Commun (Camb) 50 5583-5585 (2014)
  161. Recent Advances in the Rational Design and Optimization of Antibacterial Agents. Jones JA, Virga KG, Gumina G, Hevener KE. Medchemcomm 7 1694-1715 (2016)
  162. Small AntiMicrobial Peptide With in Vivo Activity Against Sepsis. Boullet H, Bentot F, Hequet A, Ganem-Elbaz C, Bechara C, Pacreau E, Launay P, Sagan S, Jolivalt C, Lacombe C, Moumné R, Karoyan P. Molecules 24 E1702 (2019)
  163. Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5). Singh SB, Kaelin DE, Meinke PT, Wu J, Miesel L, Tan CM, Olsen DB, Lagrutta A, Fukuda H, Kishii R, Takei M, Takeuchi T, Takano H, Ohata K, Kurasaki H, Nishimura A, Shibata T, Fukuda Y. Bioorg Med Chem Lett 25 3630-3635 (2015)
  164. The influence of like-charge attraction on the structure and dynamics of ionic liquids: NMR chemical shifts, quadrupole coupling constants, rotational correlation times and failure of Stokes-Einstein-Debye. Strate A, Overbeck V, Lehde V, Neumann J, Bonsa AM, Niemann T, Paschek D, Michalik D, Ludwig R. Phys Chem Chem Phys 20 5617-5625 (2018)
  165. Using rapid point-of-care tests to inform antibiotic choice to mitigate drug resistance in gonorrhoea. Vegvari C, Grad YH, White PJ, Didelot X, Whittles LK, Scangarella-Oman NE, Mitrani-Gold FS, Dumont E, Perry CR, Gilchrist K, Hossain M, Mortimer TD, Anderson RM, Gardiner D. Euro Surveill 25 (2020)
  166. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with Staphylococcus aureus DNA Gyrase. Morgan H, Lipka-Lloyd M, Warren AJ, Hughes N, Holmes J, Burton NP, Mahenthiralingam E, Bax BD. Int J Mol Sci 24 1634 (2023)
  167. A Fine-Tuned Lipophilicity/Hydrophilicity Ratio Governs Antibacterial Potency and Selectivity of Bifurcated Halogen Bond-Forming NBTIs. Kolarič A, Kokot M, Hrast M, Weiss M, Zdovc I, Trontelj J, Žakelj S, Anderluh M, Minovski N. Antibiotics (Basel) 10 862 (2021)
  168. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation. Zhao W, Chen L, Li HM, Wang DJ, Li DS, Chen T, Yuan ZP, Tang YJ. Bioorg Med Chem 22 2998-3007 (2014)
  169. Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague. Nguyen D, Shaik JS, Tai G, Tiffany C, Perry C, Dumont E, Gardiner D, Barth A, Singh R, Hossain M. Br J Clin Pharmacol 88 416-428 (2022)
  170. Complete Genome Sequence of Hospital-Acquired Methicillin-Resistant Staphylococcus aureus Strain WCUH29. Lei T, Zhang Y, Yang J, Silverstein K, Ji Y. Microbiol Resour Announc 8 e00551-19 (2019)
  171. Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants. Perry C, Hossain M, Powell M, Raychaudhuri A, Scangarella-Oman N, Tiffany C, Xu S, Dumont E, Janmohamed S. Infect Dis Ther 11 2297-2310 (2022)
  172. Design, Synthesis and Biological Evaluation of New Piperazin-4-yl-(acetyl-thiazolidine-2,4-dione) Norfloxacin Analogues as Antimicrobial Agents. Marc G, Araniciu C, Oniga SD, Vlase L, Pîrnău A, Nadăș GC, Novac CȘ, Matei IA, Chifiriuc MC, Măruțescu L, Oniga O. Molecules 24 E3959 (2019)
  173. Design, synthesis, antibacterial evaluation and docking study of novel 2-hydroxy-3-(nitroimidazolyl)-propyl-derived quinolone. Li Q, Xing J, Cheng H, Wang H, Wang J, Wang S, Zhou J, Zhang H. Chem Biol Drug Des 85 79-90 (2015)
  174. Diversity and Functions of Type II Topoisomerases. Sutormin DA, Galivondzhyan AK, Polkhovskiy AV, Kamalyan SO, Severinov KV, Dubiley SA. Acta Naturae 13 59-75 (2021)
  175. In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus. Barman TK, Kumar M, Mathur T, Namba E, Singh D, Chaira T, Kurosaka Y, Yamada M, Upadhyay DJ, Masuda N. Antimicrob Agents Chemother 62 e02556-17 (2018)
  176. Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects. Tiffany C, Dumont EF, Hossain M, Srinivasan M, Swift B. Clin Transl Sci 15 2251-2264 (2022)
  177. Regio- and Enantioselective Synthesis of 1,2-Diamine Derivatives by Copper-Catalyzed Hydroamination. Ichikawa S, Dai XJ, Buchwald SL. Org Lett 21 4370-4373 (2019)
  178. Structure-activity studies of divin: an inhibitor of bacterial cell division. Zhou M, Eun YJ, Guzei IA, Weibel DB. ACS Med Chem Lett 4 880-885 (2013)
  179. Synthesis of thieno[2,3-b]quinoline and selenopheno[2,3-b]quinoline derivatives via iodocyclization reaction and a DFT mechanistic study. Sonawane AD, Garud DR, Udagawa T, Koketsu M. Org Biomol Chem 16 245-255 (2018)
  180. antibacTR: dynamic antibacterial-drug-target ranking integrating comparative genomics, structural analysis and experimental annotation. Panjkovich A, Gibert I, Daura X. BMC Genomics 15 36 (2014)
  181. Thymus musilii Velen. Methanolic Extract: In Vitro and In Silico Screening of Its Antimicrobial, Antioxidant, Anti-Quorum Sensing, Antibiofilm, and Anticancer Activities. Noumi E, Ahmad I, Bouali N, Patel H, Ghannay S, ALrashidi AA, Abdulhakeem MA, Patel M, Ceylan O, Badraoui R, Mousa Elayyan AE, Adnan M, Kadri A, Snoussi M. Life (Basel) 13 62 (2022)
  182. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors. D'Atanasio N, Capezzone de Joannon A, Di Sante L, Mangano G, Ombrato R, Vitiello M, Bartella C, Magarò G, Prati F, Milanese C, Vignaroli C, Di Giorgio FP, Tongiani S. PLoS One 15 e0228509 (2020)
  183. Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes. Huang SN, Michaels SA, Mitchell BB, Majdalani N, Vanden Broeck A, Canela A, Tse-Dinh YC, Lamour V, Pommier Y. Sci Adv 7 eabe0384 (2021)
  184. Flavone-based analogues inspired by the natural product simocyclinone D8 as DNA gyrase inhibitors. Verghese J, Nguyen T, Oppegard LM, Seivert LM, Hiasa H, Ellis KC. Bioorg Med Chem Lett 23 5874-5877 (2013)
  185. Identification of a Novel Ciprofloxacin Tolerance Gene, aciT, Which Contributes to Filamentation in Acinetobacter baumannii. Naidu V, Shah B, Kamath KS, Chien A, Nagy S, Pokhrel A, Molloy M, Hassan KA, Paulsen IT. Antimicrob Agents Chemother 65 e01400-20 (2021)
  186. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases. Charrier C, Salisbury AM, Savage VJ, Moyo E, Forward H, Ooi N, Cheung J, Metzger R, McGarry D, Walker R, Cooper IR, Ratcliffe AJ, Stokes NR. J Antimicrob Chemother 71 2831-2839 (2016)
  187. Isolation, Structure Elucidation and In Silico Prediction of Potential Drug-Like Flavonoids from Onosma chitralicum Targeted towards Functionally Important Proteins of Drug-Resistant Bad Bugs. Khan SA, Khan SU, Fozia, Ullah N, Shah M, Ullah R, Ahmad I, Alotaibi A. Molecules 26 2048 (2021)
  188. Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944). Nuzzo A, Van Horn S, Traini C, Perry CR, Dumont EF, Scangarella-Oman NE, Gardiner DF, Brown JR. BMC Microbiol 21 181 (2021)
  189. Novel Glycoconjugate of 8-Fluoro Norfloxacin Derivatives as Gentamicin-resistant Staphylococcus aureus Inhibitors: Synthesis and Molecular Modelling Studies. Azad CS, Bhunia SS, Krishna A, Shukla PK, Saxena AK. Chem Biol Drug Des 86 440-446 (2015)
  190. Phytochemical Analysis, Antioxidant, and Antimicrobial Activities of Ducrosia flabellifolia: A Combined Experimental and Computational Approaches. Snoussi M, Ahmad I, Aljohani AMA, Patel H, Abdulhakeem MA, Alhazmi YS, Tepe B, Adnan M, Siddiqui AJ, Sarikurkcu C, Riadh B, Feo V, Alreshidi M, Noumi E. Antioxidants (Basel) 11 2174 (2022)
  191. Reprint of "The mechanism of negative DNA supercoiling: a cascade of DNA-induced conformational changes prepares gyrase for strand passage". Gubaev A, Klostermeier D. DNA Repair (Amst) 20 130-141 (2014)
  192. Structural and biochemical basis for DNA and RNA catalysis by human Topoisomerase 3β. Yang X, Saha S, Yang W, Neuman KC, Pommier Y. Nat Commun 13 4656 (2022)
  193. Structure elucidation and in silico docking studies of a novel furopyrimidine antibiotics synthesized by endolithic bacterium Actinomadura sp. AL2. Bhattacharjee K, Kumar S, Palepu NR, Patra PK, Rao KM, Joshi SR. World J Microbiol Biotechnol 33 178 (2017)
  194. Structure-based design of novel combinatorially generated NBTIs as potential DNA gyrase inhibitors against various Staphylococcus aureus mutant strains. Kolaric A, Minovski N. Mol Biosyst 13 1406-1420 (2017)
  195. In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes. Hackel MA, Karlowsky JA, Canino MA, Sahm DF, Scangarella-Oman NE. Antimicrob Agents Chemother 66 e0216521 (2022)
  196. Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase. Walker SS, Labroli M, Painter RE, Wiltsie J, Sherborne B, Murgolo N, Sher X, Mann P, Zuck P, Garlisi CG, Su J, Kargman S, Xiao L, Scapin G, Salowe S, Devito K, Sheth P, Buist N, Tan CM, Black TA, Roemer T. PLoS One 12 e0180965 (2017)
  197. Antimicrobial Potential of Pithecellobium dulce Seed Extract against Pathogenic Bacteria: In Silico and In Vitro Evaluation. Aldarhami A, Bazaid AS, Alhamed AS, Alghaith AF, Ahamad SR, Alassmrry YA, Alharazi T, Snoussi M, Qanash H, Alamri A, Badraoui R, Kadri A, Binsaleh NK, Alreshidi M. Biomed Res Int 2023 2848198 (2023)
  198. Computational and Preclinical Prediction of the Antimicrobial Properties of an Agent Isolated from Monodora myristica: A Novel DNA Gyrase Inhibitor. Onikanni SA, Lawal B, Fadaka AO, Bakare O, Adewole E, Taher M, Khotib J, Susanti D, Oyinloye BE, Ajiboye BO, Ojo OA, Sibuyi NRS. Molecules 28 1593 (2023)
  199. DNA gyrase could be a crucial regulatory factor for growth and survival of Mycobacterium leprae. Kim H, Fukutomi Y, Nakajima C, Kim YU, Mori S, Shibayama K, Nakata N, Suzuki Y. Sci Rep 9 10815 (2019)
  200. Design and Synthesis of 2-(4-Bromophenyl)Quinoline-4-Carbohydrazide Derivatives via Molecular Hybridization as Novel Microbial DNA-Gyrase Inhibitors. Abd El-Lateef HM, Elmaaty AA, Abdel Ghany LMA, Abdel-Aziz MS, Zaki I, Ryad N. ACS Omega 8 17948-17965 (2023)
  201. Design, Synthesis, in vitro and in silico Characterization of 2-Quinolone-L-alaninate-1,2,3-triazoles as Antimicrobial Agents. Moussaoui O, Bhadane R, Sghyar R, Ilaš J, El Hadrami EM, Chakroune S, Salo-Ahen OMH. ChemMedChem 17 e202100714 (2022)
  202. Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes. Shapiro AB, Newman J, Goteti K, Beaudoin ME, Harrison R, Hopkins S, Agrawal N, Rivin O. Antimicrob Agents Chemother 57 4816-4824 (2013)
  203. Increasing the distance between two monomers of topoisomerase IIβ under the action of antitumor agent 4β-sulfur-(benzimidazole) 4'-demethylepipodophyllotoxin. Sun LY, Zhu LW, Tang YJ. Sci Rep 8 14949 (2018)
  204. Newly discovered chroman-2,4-diones neutralize the in vivo DNA damage induced by alkylation through the inhibition of Topoisomerase IIα: A story behind the molecular modeling approach. Mladenović M, Stanković N, Matić S, Stanić S, Mihailović M, Mihailović V, Katanić J, Boroja T, Vuković N. Biochem Pharmacol 98 243-266 (2015)
  205. Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Fishman C, Caverly Rae JM, Posobiec LM, Laffan SB, Lerman SA, Pearson N, Janmohamed S, Dumont E, Nunn-Floyd D, Stanislaus DJ. Antimicrob Agents Chemother 66 e0048322 (2022)
  206. Novel and Structurally Diversified Bacterial DNA Gyrase Inhibitors Discovered through a Fluorescence-Based High-Throughput Screening Assay. Alfonso EE, Deng Z, Boaretto D, Hood BL, Vasile S, Smith LH, Chambers JW, Chapagain P, Leng F. ACS Pharmacol Transl Sci 5 932-944 (2022)
  207. Novobiocin Susceptibility of MukBEF-Deficient Escherichia coli Is Combinatorial with Efflux and Resides in DNA Topoisomerases. Petrushenko ZM, Zhao H, Zgurskaya HI, Rybenkov VV. Antimicrob Agents Chemother 60 2949-2953 (2016)
  208. Resistance pattern of Escherichia coli to levofloxacin in Iran: a narrative review. Hassanshahi G, Darehkordi A, Fathollahi MS, Falahati-Pour SK, Zarandi ER, Assar S. Iran J Microbiol 12 177-184 (2020)
  209. Structurally Optimized Potent Dual-Targeting NBTI Antibacterials with an Enhanced Bifurcated Halogen-Bonding Propensity. Kokot M, Weiss M, Zdovc I, Hrast M, Anderluh M, Minovski N. ACS Med Chem Lett 12 1478-1485 (2021)
  210. Targeted Isolation of Antibiotic Brominated Alkaloids from the Marine Sponge Pseudoceratina durissima Using Virtual Screening and Molecular Networking. Lever J, Kreuder F, Henry J, Hung A, Allard PM, Brkljača R, Rix C, Taki AC, Gasser RB, Kaslin J, Wlodkowic D, Wolfender JL, Urban S. Mar Drugs 20 554 (2022)
  211. Using Chemoinformatics, Bioinformatics, and Bioassay to Predict and Explain the Antibacterial Activity of Nonantibiotic Food and Drug Administration Drugs. Kahlous NA, Bawarish MAM, Sarhan MA, Küpper M, Hasaba A, Rajab M. Assay Drug Dev Technol 15 89-105 (2017)
  212. 1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum. Lu Y, Mann CA, Nolan S, Collins JA, Parker E, Papa J, Vibhute S, Jahanbakhsh S, Thwaites M, Hufnagel D, Hazbón MH, Moreno J, Stedman TT, Wittum T, Wozniak DJ, Osheroff N, Yalowich JC, Mitton-Fry MJ. ACS Med Chem Lett 13 955-963 (2022)
  213. In Vitro and In Vivo Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections. Ahmad MN, Garg T, Singh S, Shukla R, Malik P, Krishnamurthy RV, Kaur P, Chopra S, Dasgupta A. Antimicrob Agents Chemother 66 e0056422 (2022)
  214. Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia-An In Vitro and In Vivo Study. Sanders MI, Ali E, Buer J, Steinmann J, Rath PM, Verhasselt HL, Kirchhoff L. Antibiotics (Basel) 11 192 (2022)
  215. Basis for the discrimination of supercoil handedness during DNA cleavage by human and bacterial type II topoisomerases. Jian JY, McCarty KD, Byl JAW, Guengerich FP, Neuman KC, Osheroff N. Nucleic Acids Res 51 3888-3902 (2023)
  216. Biology-Oriented Drug Synthesis (BIODS) Approach towards Synthesis of Ciprofloxacin-Dithiocarbamate Hybrids and Their Antibacterial Potential both in Vitro and in Silico. Esfahani EN, Mohammadi-Khanaposhtani M, Rezaei Z, Valizadeh Y, Rajabnia R, Bagheri M, Bandarian F, Faramarzi MA, Samadi N, Amini MR, Mahdavi M, Larijani B. Chem Biodivers 15 e1800273 (2018)
  217. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters. Barth A, Perry CR, Shabbir S, Zamek-Gliszczynski MJ, Thomas S, Dumont EF, Brimhall DB, Nguyen D, Srinivasan M, Swift B. Clin Transl Sci 16 647-661 (2023)
  218. De novo design of novel DNA-gyrase inhibitors based on 2D molecular fingerprints. Huang Z, Lin K, You Q. Bioorg Med Chem Lett 23 4166-4171 (2013)
  219. Discovery of Novel Inhibitors of Bacterial DNA Gyrase Using a QSAR-Based Approach. Jakhar R, Khichi A, Kumar D, Dangi M, Chhillar AK. ACS Omega 7 32665-32678 (2022)
  220. Exploring Alternative Pathways to Target Bacterial Type II Topoisomerases Using NBTI Antibacterials: Beyond Halogen-Bonding Interactions. Kokot M, Novak D, Zdovc I, Anderluh M, Hrast M, Minovski N. Antibiotics (Basel) 12 930 (2023)
  221. Paired electrolysis enabled annulation for the quinolyl-modification of bioactive molecules. You S, Ruan M, Lu C, Liu L, Weng Y, Yang G, Wang S, Alhumade H, Lei A, Gao M. Chem Sci 13 2310-2316 (2022)
  222. Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1. Kirk R, Kirk R, Ratcliffe A, Noonan G, Uosis-Martin M, Lyth D, Bardell-Cox O, Massam J, Schofield P, Hindley S, Jones DR, Maclean J, Smith A, Savage V, Mohmed S, Charrier C, Salisbury AM, Moyo E, Metzger R, Chalam-Judge N, Cheung J, Stokes NR, Best S, Craighead M, Armer R, Huxley A. RSC Med Chem 11 1366-1378 (2020)
  223. Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones. Marks KR, Malik M, Mustaev A, Hiasa H, Drlica K, Kerns RJ. Bioorg Med Chem Lett 21 4585-4588 (2011)
  224. Synthesis and molecular docking of new N4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors. Mohammed HHH, Ali DME, Badr M, Habib AGK, Mahmoud AM, Farhan SM, Gany SSHAE, Mohamad SA, Hayallah AM, Abbas SH, Abuo-Rahma GEA. Mol Divers 27 1751-1765 (2023)
  225. Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase. Hurley KA, Santos TMA, Fensterwald MR, Rajendran M, Moore JT, Balmond EI, Blahnik BJ, Faulkner KC, Foss MH, Heinrich VA, Lammers MG, Moore LC, Reynolds GD, Shearn-Nance GP, Stearns BA, Yao ZW, Shaw JT, Weibel DB. Medchemcomm 8 942-951 (2017)
  226. The MksG nuclease is the executing part of the bacterial plasmid defense system MksBEFG. Weiß M, Giacomelli G, Assaya MB, Grundt F, Haouz A, Peng F, Petrella S, Wehenkel AM, Bramkamp M. Nucleic Acids Res 51 3288-3306 (2023)
  227. In Vitro Activity of Novel Topoisomerase Inhibitors against Francisella tularensis and Burkholderia pseudomallei. Whelan AO, Cooper I, Ooi N, Orr D, Blades K, Kirkham J, Lyons A, Barnes KB, Richards MI, Salisbury AM, Craighead M, Harding SV. Antibiotics (Basel) 12 983 (2023)
  228. In Vitro and In Vivo Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor. Blais J, Dean CR, Lapointe G, Leeds JA, Ma S, Morris L, Moser HE, Osborne CS, Prosen KR, Richie D, Skepper C, Thompson K, Vo J, Yue Q, Rivkin A. Antimicrob Agents Chemother 66 e0092122 (2022)
  229. A new class of antiparasitic drugs. Aphasizhev R, Aphasizheva I. Science 380 1320-1321 (2023)
  230. Actions of a Novel Bacterial Topoisomerase Inhibitor against Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks. Dauda SE, Collins JA, Byl JAW, Lu Y, Yalowich JC, Mitton-Fry MJ, Osheroff N. Int J Mol Sci 24 12107 (2023)
  231. Antimicrobial Activity of Gepotidacin Tested against Escherichia coli and Staphylococcus saprophyticus Isolates Causing Urinary Tract Infections in Medical Centers Worldwide (2019 to 2020). Arends SJR, Butler D, Scangarella-Oman N, Castanheira M, Mendes RE. Antimicrob Agents Chemother 67 e0152522 (2023)
  232. Editorial Beating bad bugs. Nat Rev Drug Discov 9 663 (2010)
  233. Bioassay's Directed Isolation-Structure Elucidation and Molecular Docking of Triterpenes from Persea duthiei against Biologically Important Microbial Proteins. Ullah N, Zeb S, Fozia, Rukh S, Khan S, Ahmad I, Ahmad S, Ahmad N, Alotaibi A, Ullah R. Evid Based Complement Alternat Med 2022 3839271 (2022)
  234. Cryo-EM structures of African swine fever virus topoisomerase. Zhao Y, Kuang W, An Q, Li J, Wang Y, Deng Z. mBio e0122823 (2023)
  235. Design, Synthesis, and Antimicrobial Activity Evaluation of Ciprofloxacin-Indole Hybrids. Song M, Hua Y, Liu Y, Xiao X, Yu H, Deng X. Molecules 28 6325 (2023)
  236. Discovery of a Series of Indane-Containing NBTIs with Activity against Multidrug-Resistant Gram-Negative Pathogens. Cumming JG, Kreis L, Kühne H, Wermuth R, Vercruysse M, Kramer C, Rudolph MG, Xu Z. ACS Med Chem Lett 14 993-998 (2023)
  237. Effect of chemical denaturants on the conformational stability of GyrB subunit of DNA gyrase from Salmonella enterica serovar Typhi. Gupta D, Sachdeva E, Haque MA, Rahman S, Bansal R, Ethayathulla AS, Hassan MI, Kaur P. Int J Biol Macromol 103 165-174 (2017)
  238. Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study. Perry CR, Scangarella-Oman NE, Millns H, Flight W, Gatsi S, Jakielaszek C, Janmohamed S, Lewis DA. Infect Dis Ther 12 2307-2320 (2023)
  239. Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge. Jakielaszek C, Hilliard JJ, Mannino F, Hossain M, Qian L, Fishman C, Chou YL, Henning L, Novak J, Demons S, Hershfield J, O'Dwyer K. Antimicrob Agents Chemother 67 e0138122 (2023)
  240. Fe(III)-montmorillonite catalysed one pot synthesis of 5-substituted dihydropyrimidine derivatives as potent antimicrobial agents. B M V, Bodke YD, Telkar S, M AS, Venkatesh T. J Taibah Univ Med Sci 12 60-69 (2017)
  241. Fluoroquinolone Analogs, SAR Analysis, and the Antimicrobial Evaluation of 7-Benzimidazol-1-yl-fluoroquinolone in In Vitro, In Silico, and In Vivo Models. Medellín-Luna MF, Hernández-López H, Castañeda-Delgado JE, Martinez-Gutierrez F, Lara-Ramírez E, Espinoza-Rodríguez JJ, García-Cruz S, Portales-Pérez DP, Cervantes-Villagrana AR. Molecules 28 6018 (2023)
  242. Intracellular Experimental Evolution of Francisella tularensis Subsp. holarctica Live Vaccine Strain (LVS) to Antimicrobial Resistance. Mehta HH, Song X, Shamoo Y. ACS Infect Dis 9 308-321 (2023)
  243. Novel Fluoroquinolones with Possible Antibacterial Activity in Gram-Negative Resistant Pathogens: In Silico Drug Discovery. Coba-Males MA, Lavecchia MJ, Alcívar-León CD, Santamaría-Aguirre J. Molecules 28 6929 (2023)
  244. Novel Indane-Containing NBTIs with Potent Anti-Gram-Negative Activity and Minimal hERG Inhibition. Cumming JG, Kreis L, Kühne H, Wermuth R, Vercruysse M, Cantrill C, Bissantz C, Qiu H, Kramer C, Andreotti D, Fossati G. ACS Med Chem Lett 14 1791-1799 (2023)
  245. Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs. Mann CA, Carvajal Moreno JJ, Lu Y, Dellos-Nolan S, Wozniak DJ, Yalowich JC, Mitton-Fry MJ. Antimicrob Agents Chemother 67 e0048223 (2023)
  246. Nybomycin inhibits both types of E. coli DNA gyrase - fluoroquinolone-sensitive and fluoroquinolone-resistant. Shiriaev DI, Sofronova AA, Berdnikovich EA, Lukianov DA, Komarova ES, Marina VI, Zakalyukina YV, Biryukov MV, Maviza TP, Ivanenkov YA, Sergiev PV, Osterman IA, Dontsova OA. Antimicrob Agents Chemother 95 AAC.00777-20 (2023)
  247. Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants. Barth A, Hossain M, Perry CR, Gross AS, Ogura H, Shabbir S, Thomas S, Dumont EF, Brimhall DB, Srinivasan M, Swift B. Clin Pharmacol Drug Dev 12 38-56 (2023)
  248. Potent Inhibition of Bacterial DNA Gyrase by Digallic Acid and Other Gallate Derivatives. Alfonso EE, Troche R, Deng Z, Annamalai T, Chapagain P, Tse-Dinh YC, Leng F. ChemMedChem 17 e202200301 (2022)
  249. Structure-Activity Relationship of Anti-Mycobacterium abscessus Piperidine-4-carboxamides, a New Class of NBTI DNA Gyrase Inhibitors. Beuchel A, Robaa D, Negatu DA, Madani A, Alvarez N, Zimmerman MD, Richter A, Mann L, Hoenke S, Csuk R, Dick T, Imming P. ACS Med Chem Lett 13 417-427 (2022)
  250. Synthesis and investigation of binding interactions of 1,4-benzoxazine derivatives on topoisomerase IV in Acinetobacter baumannii. Yilmaz S, Yalcin I, Okten S, Onurdag FK, Aki-Yalcin E. SAR QSAR Environ Res 28 941-956 (2017)
  251. Synthesis, X-ray diffraction study, analysis of inter-molecular inter-actions and mol-ecular docking of ethyl 1-(3-tosyl-quinolin-4-yl)piperidine-4-carboxyl-ate. Vaksler Y, Hryhoriv HV, Kovalenko SM, Perekhoda LO, Georgiyants VA. Acta Crystallogr E Crystallogr Commun 78 890-896 (2022)
  252. Synthesis, biological and molecular modelling for 1,3,4-thiadiazole sulfonyl thioureas: bacterial and fungal activity. Dinh Thanh N, Ngoc Toan V, Thi Kim Giang N, Thi Kim Van H, Son Hai D, Minh Tri N, Ngoc Toan D. RSC Med Chem 14 2751-2767 (2023)
  253. The bile salt deoxycholate induces Campylobacter jejuni genetic point mutations that promote increased antibiotic resistance and fitness. Talukdar PK, Crockett TM, Gloss LM, Huynh S, Roberts SA, Turner KL, Lewis STE, Herup-Wheeler TL, Parker CT, Konkel ME. Front Microbiol 13 1062464 (2022)
  254. Thiourea derivatives containing 4-arylthiazoles and d-glucose moiety: design, synthesis, antimicrobial activity evaluation, and molecular docking/dynamics simulations. Thanh ND, Lan PH, Hai DS, Anh HH, Giang NTK, Van HTK, Toan VN, Tri NM, Toan DN. RSC Med Chem 14 1114-1130 (2023)


Quick links